Smith & Nephew IV3000 Transparent Dressings 4"x4 3/4", Pack of 10 Dressings, ...

Product Information

Using Tegaderm CHG instead of a standard dressing does not need any special additional training. At the topic selection phase, the Committee received expert advice that confirmed that minimal additional training would be needed.

If the dressing is soiled with blood or there is wetness under the dressing it will need to be changed as this increases the risk of infection The company searched the Medicines and Healthcare Products Regulatory Agency (MHRA), Food and Drug Administration (FDA) and Manufacturer and User Facility Device Experience (MAUDE) systems to identify surveillance reports relating to Tegaderm CHG, between 7 January 2000 and 29 July 2013. This revealed 1 result from the MHRA and 109 results from MAUDE. The company also searched its post‑marketing surveillance data for reported skin reactions. This identified a marked reduction in reports, both in numbers and relative to increasing sales, after a modification to the dressing design in 2011 to incorporate a breathable film. Cheyne Child Development: while you wait leaflet - Pre-School Age (Hammersmith and Fulham children)

Frequency of Change

Krauss EM, Lalonde DH. Secondary healing of fingertip amputations: a review. Hand 2014;9(3):282–288. CONCLUSION: In conclusion, the IV-3000 wound management protocol is an excellent option for patients unsuited to surgical treatment of fingertip wounds, and it may be easily implemented by plastic surgeons in their daily clinical practice. The dressing allows for outpatient management of fingertip wounds while yielding results that are excellent in terms of aesthetics and preserved digit function. The External Assessment Centre found that the company's search of the MAUDE and MHRA systems accurately reported, in detail, the adverse events for Tegaderm CHG. Overall, it considered the company's search for adverse events to be robust. The External Assessment Centre extended the company's search to 28 November 2014 and identified a further 17 results. These results generally described local skin reactions within 48 hours of dressing application, and many were self‑limiting. There were 2 deaths reported in MAUDE, but these were not directly linked to Tegaderm CHG. Advice provided during evaluation from 3 experts with experience of using both Tegaderm CHG and standard dressings was that, in general, clinician experience of applying and removing Tegaderm CHG was similar to standard dressings. There was 1 expert who stated that it takes longer to remove Tegaderm CHG and that there may be a few incorrect applications at first. The remaining 2 experts stated that the time taken to apply or remove the dressing is the same or similar for both Tegaderm CHG and standard dressings.

MATERIALS AND METHODS: All patients with simple distal fingertip injury were treated using the IV-3000 dressing protocol during the study period. This original protocol involves creating a sandwich of two adhesive IV-3000 patches around the digit. Patients reapplied the dressing at home every three to four days and were evaluated in office for re-epithelialization and digit function. Then wrap a piece of gauze around it to make the clamps fit more securely this also prevents damage that the clamps can do to the central line. The end should not be dangling down by the nappy/groin area, if they do get soiled, the bionector (caps) at the end of the line will need to be changed and the line should be cleaned thoroughly.The end of the central line can be taped out of the way when your child has a bath, please ensure that the end does not get submerged in the bath. Some families find it useful to place the bung in a plastic bag, using cling film or a sandwich bag and also tap the line(s) over the shoulders during bath time. NHS Clinical Evaluation Team 2018. Clinical Review: Intravenous Vapour Permeable Film Dressings (IV Films) - Part One Securing Peripheral Cannulae in Adults (PVAD). UK. DISCLOSURES: None of the authors have a financial interest in any of the products, devices, or drugs mentioned in this manuscript.